- Headquarters
- Burlington, Massachusetts
- Employees
- 1–10
- Founded
- 1993
- Business Model
- B2B
- Website
- arqule.com
- Acquired by
- Merck & Co.Jan 2020 · $2.7B
About
Incorporated in 1993 and headquartered in Burlington, Massachusetts, ArQule was one of the first biotech companies to focus on the chemistry aspect of drug discovery for cancer. The company developed targeted therapeutics for cancers and rare diseases using a kinase inhibitor platform, with its lead compound ARQ 531 showing durable responses in patients with B-cell malignancies. Merck acquired ArQule in January 2020 for approximately $2.7 billion, adding ARQ 531 (later nemtabrutinib) to its oncology pipeline.
Summary
ArQule is a Biotech company based in Burlington, United States, founded in 1993. Investors include Merck Life Sciences.
Exit History
2020 (est.)
Investors
Similar Companies
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Novel bicyclic peptides and drug conjugates for cancer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/arqule"><img src="https://indexed.vc/api/badge/company/arqule" alt="ArQule on Indexed.vc" width="260" height="76" /></a>